Latest News and Updates | Cantargia

* (R) = Regulatory press releases

Apr 25, 2025

Cantargia presents promising preclinical results on anti-IL1RAP antibody-drug conjugate (ADC) at a major cancer conference

Apr 25, 2025

Cantargia presents association between nadunolimab and reduction of chemotherapy induced peripheral neuropathy (CIPN) at AACR

Apr 11, 2025

(R) Cantargia publishes Annual Report 2024

Apr 11, 2025

(R) Notice of annual general meeting in Cantargia AB (publ)

Apr 1, 2025

(R) Cantargia appoints Morten Lind Jensen as Chief Medical Officer

Mar 25, 2025

Cantargia presents promising preclinical results on a novel IL1RAP-targeting antibody-drug conjugate at AACR 2025.

Mar 25, 2025

Cantargia publishes an abstract on parallel anti-tumor activity and reduction of chemotherapy-induced neuropathy with nadunolimab

Mar 13, 2025

Cantargia to Participate at Van Lanschot Kempen’s Life Sciences Conference

Mar 12, 2025

(R) First patient enrolled in Cantargia’s leukemia study with nadunolimab

Mar 10, 2025

Cantargia’s TRIFOUR phase 2 study investigating nadunolimab in triple negative breast cancer fully recruited

<< Newer press releases Older press releases >>

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye